Modified HIV Envelope Prime-Boost Immunogens for bnAb Induction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current HIV-1 vaccines fail to induce high levels of broadly neutralizing antibodies (bnAbs), which are crucial for effective protection against HIV-1 infection, particularly in developing countries where antiretroviral treatment (ART) is not readily available.

Innovation Solution

The development of immunogenic compositions comprising selected HIV-1 envelope proteins and nucleic acids, including recombinant proteins and nucleic acids encoding them, designed to target precursors and unmutated common ancestors (UCAs) of bnAbs, with modifications such as multimerization and variable region sequence optimization, and administered as prime and boost immunogens to induce cross-reactive neutralizing antibodies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current HIV-1 vaccines are used, then vaccination can be administered, but they fail to induce high levels of broadly neutralizing antibodies

Engineering Contradiction:

Improveinduction of broadly neutralizing antibodiesVSAvoidlevels of neutralizing antibodies

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The vaccine regimen is divided into multiple immunization visits with different envelope sequences (prime and boost doses), allowing the immune system to progressively develop bnAbs through staged antigen presentation of diverse HIV-1 envelope variants

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The immunogen design dynamically presents multiple envelope sequences that evolve to mimic natural bnAb maturation pathways, with each immunization visit presenting a progressively optimized envelope sequence based on observed antibody evolution

Inventive Principle:

Principle #15Dynamics

2Reliability

If antiretroviral treatment is provided, then HIV-1 infection can be controlled, but it is not routinely available in developing countries

Engineering Contradiction:

Improveprotection against HIV-1 infectionVSAvoidavailability in developing countries

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The vaccine copies the protective immune response mechanism by inducing bnAbs that mimic the effect of ART, providing protective immunity without requiring continuous antiretroviral medication, thus making protection accessible in settings where ART is not routinely available

Inventive Principle:

Principle #26Copying

3Reliability

If HIV-1 envelope immunogens are designed to target precursors and unmutated common ancestors, then cross-reactive neutralizing antibodies can be induced, but the immunogen design complexity increases

Engineering Contradiction:

Improvecross-reactive neutralizing antibody inductionVSAvoidimmunogen design complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The immunogen design incorporates pre-identified precursor and unmutated common ancestor envelope sequences that are known to elicit bnAbs, presenting these sequences in advance during prime and boost immunizations to guide antibody maturation toward protective specificities

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The envelope sequences are systematically modified at specific positions (such as position 327) to optimize binding to bnAb precursors and UCAs, with controlled mutations designed to enhance immunogenicity while maintaining structural integrity and manufacturability

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250340597A1Compositions comprising HIV envelopes to induce HIV-1 antibodies

Publication Date: 2025.11.06 DUKE UNIV

AI summary

The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.